Group 1 - The core viewpoint of the article highlights the financial performance and stock movement of Lakeshore Biosciences (LSB), indicating a positive trend in both revenue and net profit [1] - As of August 18, LSB's stock price increased by 3.36%, reaching $0.806 per share, with a total market capitalization of $33.2257 million [1] - Financial data shows that by March 31, 2025, LSB's total revenue amounted to 615 million RMB, reflecting a year-on-year growth of 7.24% [1] Group 2 - The net profit attributable to the parent company was reported at -99.9825 million RMB, which represents a significant year-on-year increase of 76.93% [1] - Lakeshore Biosciences is a Cayman Islands-registered holding company, primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1] - Beijing Yisheng Biotechnology is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

8月18日，湖岸生物(LSB)开盘上涨8.97%，截至21:30，报0.85美元/股，成交6941.0美元，总市值3503.08 万美元。 财务数据显示，截至2025年03月31日，湖岸生物收入总额6.15亿人民币，同比增长7.24%；归母净利 润-9998.25万人民币，同比增长76.93%。 资料显示，湖岸生物技术有限公司是一家在开曼群岛注册成立的境外控股母公司,主要由其境内实体子 公司北京依生生物技术有限公司运营。依生生物技术有限公司是一家全球性的生物制药公司,致力于发 现、开发、生产和商业化新一代疫苗和治疗性生物制剂,用于治疗传染病和癌症。 本文源自：金融界 作者：行情君 ...

Core Insights - Lakeshore Biotech (LSB) experienced a stock price increase of 3.67%, reaching $0.819 per share with a total market capitalization of $33.75 million as of August 16 [1] - As of March 31, 2025, Lakeshore Biotech reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1] - The company recorded a net profit attributable to shareholders of -99.98 million RMB, which represents a significant year-on-year increase of 76.93% [1] - Lakeshore Biotech is a Cayman Islands-registered holding company primarily operated by its domestic subsidiary, Beijing Yisheng Biotech Co., Ltd., which focuses on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

Core Viewpoint - Lakeshore Biotech (LSB) has shown a positive market performance with a 3.13% increase in stock price, reaching $0.79 per share, and a total market capitalization of $32.55 million [1] Financial Performance - As of March 31, 2025, Lakeshore Biotech reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1] - The company experienced a significant increase in net profit attributable to shareholders, amounting to -99.98 million RMB, which represents a year-on-year growth of 76.93% [1] Company Overview - Lakeshore Biotech is a Cayman Islands-registered holding company, primarily operated by its domestic subsidiary, Beijing Yisheng Biotech Co., Ltd. [1] - Beijing Yisheng Biotech Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

Core Viewpoint - Lakeshore Biosciences (LSB) has shown a positive stock performance with a 2.38% increase, reaching $0.829 per share, and a total market capitalization of $34.18 million [1] Financial Performance - As of March 31, 2025, Lakeshore Biosciences reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1] - The company experienced a net loss attributable to shareholders of 99.98 million RMB, which represents a significant year-on-year improvement of 76.93% [1] Company Overview - Lakeshore Biosciences is a Cayman Islands-registered holding company primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1] - Beijing Yisheng Biotechnology Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

Core Viewpoint - Lakeshore Bio (LSB) experienced a significant stock price increase of 10.73%, reaching $0.775 per share, with a total market capitalization of $31.94 million as of August 12 [1] Financial Performance - As of March 31, 2025, Lakeshore Bio reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1] - The company recorded a net loss attributable to shareholders of 99.98 million RMB, which represents a year-on-year improvement of 76.93% [1] Company Overview - Lakeshore Bio Technology Co., Ltd. is a Cayman Islands-registered holding company primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1] - Beijing Yisheng Biotechnology Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

资料显示，湖岸生物技术有限公司是一家在开曼群岛注册成立的境外控股母公司,主要由其境内实体子 公司北京依生生物技术有限公司运营。依生生物技术有限公司是一家全球性的生物制药公司,致力于发 现、开发、生产和商业化新一代疫苗和治疗性生物制剂,用于治疗传染病和癌症。 本文源自：金融界 作者：行情君 8月11日，湖岸生物(LSB)盘中上涨2.86%，截至21:55，报0.72美元/股，成交702.0美元，总市值2967.31 万美元。 财务数据显示，截至2025年03月31日，湖岸生物收入总额6.15亿人民币，同比增长7.24%；归母净利 润-9998.25万人民币，同比增长76.93%。 ...

Core Viewpoint - Lakeshore Bio (LSB) shows a positive market response with a 3.03% increase in stock price, reflecting investor confidence in the company's financial performance and growth potential [1]. Financial Performance - As of March 31, 2025, Lakeshore Bio reported total revenue of 615 million RMB, representing a year-on-year growth of 7.24% [1]. - The company achieved a net profit attributable to shareholders of -99.98 million RMB, which indicates a significant year-on-year increase of 76.93% [1]. Company Overview - Lakeshore Bio Technology Co., Ltd. is a Cayman Islands-registered holding company, primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1]. - Beijing Yisheng Biotechnology Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1].

Core Viewpoint - Lakeshore Bio (LSB) shows a positive market performance with a 2.49% increase in stock price, reaching $0.679 per share, and a total market capitalization of $27.9834 million [1] Financial Performance - As of March 31, 2025, Lakeshore Bio reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1] - The company experienced a significant increase in net profit attributable to shareholders, amounting to -99.9825 million RMB, which represents a year-on-year growth of 76.93% [1] Company Overview - Lakeshore Bio Technology Co., Ltd. is a Cayman Islands-registered holding company, primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1] - Beijing Yisheng Biotechnology Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

8月6日，湖岸生物(LSB)盘中上涨6.79%，截至21:36，报0.77美元/股，成交562.0美元，总市值3171.32万 美元。 本文源自：金融界 作者：行情君 资料显示，湖岸生物技术有限公司是一家在开曼群岛注册成立的境外控股母公司,主要由其境内实体子 公司北京依生生物技术有限公司运营。依生生物技术有限公司是一家全球性的生物制药公司,致力于发 现、开发、生产和商业化新一代疫苗和治疗性生物制剂,用于治疗传染病和癌症。 财务数据显示，截至2025年03月31日，湖岸生物收入总额6.15亿人民币，同比增长7.24%；归母净利 润-9998.25万人民币，同比增长76.93%。 ...